UCB showcases three-year hidradenitis suppurativa data on Bimzelx

Belgium’s largest drugmaker UCB (Euronext: UCB) today announced three-year data from the BE HEARD trials^ for Bimzelx (bimekizumab) in moderate to severe HS.

Bimekizumab, the first and only medicine approved to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL‑17F), demonstrated total resolution of inflammatory lesions and substantial improvements in disease severity, sustained to three years.

Of people with HS at baseline, 40.1% (147/367) of those assessed at three years achieved IHS4‑100. In addition, 59.1% (217/367) and 77.4% (284/367) of those assessed at three years achieved IHS4‑90 and IHS4-75, respectively. In a second analysis, the proportion of people with severe HS, as assessed by IHS4, fell from 87.4% (486/556) at baseline to 14.7% (54/367) at three years.